Glenmark Pharmaceuticals 미래 성장
Future 기준 확인 4/6
Glenmark Pharmaceuticals (는) 각각 연간 70.4% 및 10.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 70.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.9% 로 예상됩니다.
주요 정보
70.4%
수익 성장률
70.2%
EPS 성장률
| Pharmaceuticals 수익 성장 | 17.7% |
| 매출 성장률 | 10.8% |
| 향후 자기자본 수익률 | 17.9% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 21 Nov 2024 |
최근 미래 성장 업데이트
Recent updates
Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now
Oct 26
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50
Sep 06Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 3/31/2027 | 170,663 | 22,170 | 12,056 | 23,837 | 10 |
| 3/31/2026 | 153,313 | 17,770 | 9,017 | 19,304 | 14 |
| 3/31/2025 | 137,177 | 14,477 | -4,562 | 6,205 | 13 |
| 9/30/2024 | 130,799 | -10,183 | -20,772 | -13,441 | N/A |
| 6/30/2024 | 128,612 | -15,732 | N/A | N/A | N/A |
| 3/31/2024 | 126,454 | -18,990 | -11,638 | -2,654 | N/A |
| 12/31/2023 | 131,575 | -7,640 | N/A | N/A | N/A |
| 9/30/2023 | 137,510 | -1,263 | 302 | 7,192 | N/A |
| 6/30/2023 | 136,144 | 2,546 | N/A | N/A | N/A |
| 3/31/2023 | 116,556 | -1,697 | 176 | 6,254 | N/A |
| 12/31/2022 | 126,355 | 8,811 | N/A | N/A | N/A |
| 9/30/2022 | 123,451 | 8,305 | -21 | 7,689 | N/A |
| 6/30/2022 | 121,173 | 8,277 | N/A | N/A | N/A |
| 3/31/2022 | 123,049 | 9,417 | 3,185 | 11,087 | N/A |
| 12/31/2021 | 122,103 | 10,202 | N/A | N/A | N/A |
| 9/30/2021 | 118,248 | 10,464 | 5,411 | 12,490 | N/A |
| 6/30/2021 | 116,144 | 10,226 | N/A | N/A | N/A |
| 3/31/2021 | 109,439 | 9,700 | 3,565 | 11,312 | N/A |
| 12/31/2020 | 107,778 | 9,565 | N/A | N/A | N/A |
| 9/30/2020 | 107,445 | 8,992 | 3,945 | 12,296 | N/A |
| 6/30/2020 | 106,629 | 9,207 | N/A | N/A | N/A |
| 3/31/2020 | 106,573 | 7,760 | 4,610 | 13,924 | N/A |
| 12/31/2019 | 104,370 | 7,173 | N/A | N/A | N/A |
| 9/30/2019 | 102,564 | 6,428 | 1,271 | 13,254 | N/A |
| 6/30/2019 | 100,227 | 7,680 | N/A | N/A | N/A |
| 3/31/2019 | 98,655 | 9,250 | 870 | 13,242 | N/A |
| 12/31/2018 | 95,532 | 8,863 | N/A | N/A | N/A |
| 9/30/2018 | 92,018 | 8,721 | N/A | N/A | N/A |
| 6/30/2018 | 89,057 | 6,716 | N/A | N/A | N/A |
| 3/31/2018 | 90,744 | 8,039 | N/A | 16,481 | N/A |
| 12/31/2017 | 91,908 | 6,420 | N/A | N/A | N/A |
| 9/30/2017 | 95,055 | 10,083 | N/A | N/A | N/A |
| 6/30/2017 | 94,896 | 10,233 | N/A | N/A | N/A |
| 3/31/2017 | 90,794 | 9,160 | N/A | 6,574 | N/A |
| 12/31/2016 | 89,316 | 10,402 | N/A | N/A | N/A |
| 9/30/2016 | 81,749 | 7,508 | N/A | N/A | N/A |
| 6/30/2016 | 78,414 | 7,292 | N/A | N/A | N/A |
| 3/31/2016 | 75,732 | 7,021 | N/A | 3,448 | N/A |
| 12/31/2015 | 70,300 | 5,697 | N/A | N/A | N/A |
| 9/30/2015 | 69,530 | 5,141 | N/A | N/A | N/A |
| 6/30/2015 | 67,244 | 4,814 | N/A | N/A | N/A |
| 3/31/2015 | 65,561 | 4,753 | N/A | 4,817 | N/A |
| 12/31/2014 | 64,891 | 5,078 | N/A | N/A | N/A |
| 9/30/2014 | 63,983 | 6,092 | N/A | N/A | N/A |
| 6/30/2014 | 61,897 | 5,984 | N/A | N/A | N/A |
| 3/31/2014 | 59,450 | 5,423 | N/A | 8,537 | N/A |
| 12/31/2013 | 56,441 | 6,660 | N/A | N/A | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: GLENMARK 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 6.7% )보다 빠른 성장으로 간주됩니다.
수익 vs 시장: GLENMARK (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.
고성장 수익: GLENMARK 향후 3년 내에 수익을 낼 것으로 예상됩니다.
수익 대 시장: GLENMARK 의 수익(연간 10.8% ) Indian 시장( 10.5% 보다 빠르게 성장할 것으로 예상됩니다. 10.5% 연간).
고성장 수익: GLENMARK 의 수익(연간 10.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: GLENMARK 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 17.9 %).